@ARTICLE{10.3389/fpsyt.2020.00435, AUTHOR={Tavares, Diego Freitas and dos Santos, Carla Garcia Rodrigues and Valiengo, Leandro Da Costa Lane and Klein, Izio and Borrione, Lucas and Forte, Pamela Marques and Brunoni, Andre R. and Moreno, Ricardo Alberto}, TITLE={Efficacy, Safety, and Tolerability of Theta-Burst Stimulation in Mixed Depression: Design, Rationale, and Objectives of a Randomized, Double-Blinded, Sham-Controlled Trial}, JOURNAL={Frontiers in Psychiatry}, VOLUME={11}, YEAR={2020}, URL={https://www.frontiersin.org/articles/10.3389/fpsyt.2020.00435}, DOI={10.3389/fpsyt.2020.00435}, ISSN={1664-0640}, ABSTRACT={IntroductionMixed-specifier mood disorders are probably a different subgroup in terms of response to treatment, socio-demographic parameters, course, and family history. Here we describe the rationale and design of a clinical trial aimed to test the efficacy, safety, and tolerability of a non-pharmacological treatment known as theta-burst stimulation (TBS) for treating the mixed depressive episodes of both bipolar (I or II), and unipolar depression.MethodsThe study is designed as a randomized, sham-controlled, double-blinded clinical trial evaluating TBS for the treatment of moderate or severe major depressive episodes with mixed features of patients receiving at least one first or second-line pharmacological treatment for depressive episodes without adequate response. Ninety adult (18 to 65 years old) patients will be enrolled and submitted to 6-week (comprising 5 consecutive days a week sessions for the first 3 weeks and then 2 days a week for a further 3 week) of inhibitory followed by excitatory TBS in dorsolateral prefrontal cortex. Participants will be assessed using clinical and neuropsychological tests before and after the intervention. The primary outcome is change in Montgomery–Åsberg Depression Scale (MADRS) score over time and across groups. Cognitive parameters will also be assessed with neuropsychological tests.ResultsThe clinical results will provide evidence about TBS as an adjunctive treatment for mixed depression treatment and neuropsychological parameters will contribute toward an improved understanding the effects of TBS in cognition.ConclusionOur results could introduce a novel therapeutic technique for mixed depressive episodes of both bipolar and unipolar disorders.Clinical Trial Registrationwww.ClinicalTrials.gov, identifier NCT04123301; date of registration: 10/10/2019; URL: https://clinicaltrials.gov/ct2/show/NCT04123301?term=NCT04123301&rank=1.} }